Serum total and high-density lipoprotein phospholipids: Independent predictive value for cardiometabolic risk

Clinical Nutrition

Volumn 33, Issue 5, 2014, Pages 815-822

  Onat, Altan ^a   Altug Cakmak H ^a   Can, Günay ^a   Yüksel, Murat ^b   Köroǧlu, Bayram ^c   Yüksel, Hüsniye ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b DICLE UNIVERSITY   (Turkey)

^c DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Apolipoprotein A I; Coronary heart disease risk; HDL cholesterol; Metabolic syndrome; Phospholipids; Population based study

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; URIC ACID;

BLOOD; CARDIOVASCULAR DISEASE; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; TURKEY; WAIST CIRCUMFERENCE;

APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHOSPHOLIPIDS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TURKEY; URIC ACID; WAIST CIRCUMFERENCE;

EID: 84906047421     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2013.10.020     Document Type: Article

References (34)

1. Lee S., Birukov G., Romanoski C.E., Springstead J.R., Lusis A.J., Berliner J.A. Role of phospholipid oxidation products in atherosclerosis. Circ Res 2012, 111:778-799.
2. Tsimikas S., Brilakis E.S., Miller E.R., McConnell J.P., Lennon R.J., Kornman K.S., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. NEngl J Med 2005, 353:46-57.
3. Leibundgut G., Arai K., Orsoni A., Yin H., Scipione C., Miller E.R., et al. Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. JAm Coll Cardiol 2012, 59:1426-1437.
4. Navab M., Reddy S.T., van Lenten B.J., Buga G.M., Hough G., Wagner A.C., et al. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. ATVB 2012, 32:2553-2560.
5. Martinez-Beamonte R., Lou-Bonafonte L., Martinez-Gracia M.V., Osada J. Sphingomyelin in high-density lipoproteins: structural role and biological function. Int J Mol Sci 2013, 14:7716-7741.
6. Wang Z., Klipfell E., Bennett B.J., Koeth R., Levison B.S., Dugar B., et al. Gut flora metabolism of posphatidylcholine promotes cardiovascular disease. Nature 2011, 472:57-63.
7. Onat A., Hergenç G. Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011, 60:499-512.
8. Onat A., Can G., Hergenç G., Uǧur M., Yüksel H. Coronary disease risk prediction algorithm warranting incorporation of C-reactive protein in Turkish adults, manifesting sex difference. Nutr Metab CV Dis 2012, 22:643-650.
9. Onat A., Hergenç G., Bulur S., Uǧur M., Küçükdurmaz Z., Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010, 142:72-79.
10. Onat A., Can G., Ayhan E., Kaya Z., Hergenç G. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 2009, 58:1393-1399.
11. Hergenç G., Onat A., Sari İ., Yazici M., Eryonucu B., Can G. Serum total and high-density lipoprotein phospholipid levels in a population-based study and relationship to risk of metabolic syndrome and coronary disease. Angiology 2008, 59:26-35.
12. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001, 156:1-10.
13. Takayama M., Itoh S., Nagasaki T., Tanimuzu I. Anew enzymatic method for the determination of serum choline-containing phospholipids. Clin Chim Acta 1977, 79:93-98.
14. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., et al. Follow-up report on the diagnosis of diabetes mellitus. The Expert Committee on theDiagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003, 26:3160-3167. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
15. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: report of the national heart, lung, and blood institute/american heart association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
16. Onat A., Uyarel H., Hergenç G., Karabulut A., Albayrak S., Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007, 191:182-190.
17. Rose G.A., Blackburn H., Gillum R.F., Prineas R.J. Cardiovascular survey methods 1982, 124-127. WHO, Geneva. 2nd ed.
18. Wang Y., Snel M., Jonker J.T., Hammer S., Lamb H.J., de Roos A., et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol efflux properties of HDL. Diabetes Care 2011, 34:2576-2580.
19. Onat A., Yüksel M., Köroǧlu B., Gümrükçüoǧlu H.A., Aydin M., Çakmak H.A., et al. Turkish adult risk factor survey 2012: overall and coronary mortality and trends in the prevalence of metabolic syndrome. Arch Turk Soc Cardiol 2013, 41:373-378. 10.5543/tkda.2013.15853.
20. Napoli C., Witztum J.L., Calara F., de Nigris F., Palinski W. Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses. Circ Res 2000, 87:946-952.
21. Corsetti J.P., Bakker S.J., Sparks C.E., Dullaart R.P. Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease in women with high levels of HDL cholesterol and C-reactive protein. PLoS One 2012, 7:e39110.
22. Onat A., Hergenç G., Can G., Kaya Z., Yüksel H. Complement C3: a determinant of cardiometabolic risk, additive to metabolic syndrome, in middle-aged population. Metabolism 2010, 59:628-634.
23. Onat A., Can G., Rezvani R., Cianflone K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 2011, 412:1171-1179.
24. MacLaren R., Cui W., Cianflone K. Adipokines and the immune system: an adipocentric view. Current topics in complement II 2008, 1-21. Springer. J.D. Lambris (Ed.).
25. Onat A., Hergenç G., Uyarel H., Karabulut A., Yazici M., Sari İ., et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 2006, 19:1055-1062.
26. Onat A., Can G. Enhanced pro-inflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharma Des. 2013 Apr 2, [Epub].
27. Lohner S., Fekete K., Marosvölgyi T., Decsi T. Gender differences in the long-chain polyunsaturated fatty acid status: systematic review of 51 publications. Ann Nutr Metab 2013, 62:98-112.
28. Efrat M., Aviram M. Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis -a protective role for HDL phospholipids. Adv Exp Med Biol 2010, 660:153-166.
29. Noori M., Darabi M., Rahbani M., Abadi N.A., Darabi M., Ghatehsamani K. Fatty acid composition of HDL phospholipids and coronary artery disease. JClin Lipidol 2009, 3:39-44.
30. Piperi C., Kalofoutis C., Papaevangeliou A., Lekakis J., Kalofoutis A. The significance of serum HDL phospholipids levels in angiographically defined coronary artery disease. Clin Biochem 2004, 37:377-381.
31. Miller Y.I., Choi S.H., Wiesner P., Fang L., Harkewicz R., Hartvigsen K., et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011, 108:235-248.
32. Onat A., Can G., Murat S., Çiçek G., Örnek E., Yüksel H. Aggregation of lipoprotein(a) to apolipoprotein A-I underlying HDL dysfunction as a major coronary risk factor. Anadolu Kardiyol Derg 2013, 13:543-551. Jul 4 [Epub]. 10.5152/akd.2013.175.
33. Perrin-Cocon L., Diaz O., Carreras M., Dollet S., Guironnet-Paquet A., André P., et al. High-density lipoprotein phospholipids interfere with dendritic cell Th1 functional maturation. Immunobiology 2012, 217:91-99.
34. 2 among Turks yielding positive and inverse associations with cardiometabolic risk. Clin Chem Lab Med 2011, 49:1349-1357.